Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02194465 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2623091 in Participants With High Blood Pressure
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 304
- Enrollment target
NCT02194465: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT02194465 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 304 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (129% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02194465, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 304 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.
Primary Outcome
Change from baseline in SBP as measured by a cuff. Least squares (LS) mean change from baseline was calculated using a mixed model repeating measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Interventions
- DRUG Placebo
- DRUG Spironolactone
- DRUG Tadalafil
- DRUG LY2623091
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
What the finished NCT02194465 record still lists
NCT02194465 is an interventional study that assigns participants to a tested intervention. The registered 304 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (129% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02194465 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02194465 about?
NCT02194465 is a clinical study titled "A Study of LY2623091 in Participants With High Blood Pressure". The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.
What is the current status of trial NCT02194465?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 304 participants. The study started on 2014-08. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02194465?
The interventions under investigation include: Placebo (DRUG), Spironolactone (DRUG), Tadalafil (DRUG), LY2623091 (DRUG).
Who is sponsoring clinical trial NCT02194465?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02194465's enrollment target sits among peer trials
304 166th of 2000 higher than 1,834 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
- NCT06096844 · 304 participants · Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia